Open observational study of galantamine hydrobromide (Reminyl) administration for the treatment of patients with mild to moderate dementia of the Alzheimer type.

Trial Profile

Open observational study of galantamine hydrobromide (Reminyl) administration for the treatment of patients with mild to moderate dementia of the Alzheimer type.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Mar 2012

At a glance

  • Drugs Galantamine (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 06 Oct 2009 Actual patient number (344) added as reported by ClinicalTrials.gov.
    • 19 Oct 2007 Status changed from in progress to completed.
    • 14 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top